candesartan cilexetil has been researched along with Kidney Failure, Chronic in 3 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan cilexetil (1 mg/kg/day) and enalapril (10 mg/kg/day) were orally administered once a day for 4 weeks (the short-term experiment) or 16 weeks (the long-term experiment) to 5/6 nephrectomized rats beginning 15 weeks after the nephrectomy, that is, after they had already showed marked proteinuria." | 3.70 | Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Naka, T; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1999) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, interstitial mononuclear cell (MNC) infiltration and interstitial fibrosis developed." | 1.30 | Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schulz, EG | 1 |
| Bahri, S | 1 |
| Schettler, V | 1 |
| Popov, AF | 1 |
| Hermann, M | 1 |
| Noda, M | 2 |
| Fukuda, R | 2 |
| Matsuo, T | 2 |
| Ohta, M | 2 |
| Nagano, H | 2 |
| Imura, Y | 2 |
| Nishikawa, K | 2 |
| Shibouta, Y | 2 |
| Naka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria[NCT00280215] | Phase 3 | 0 participants (Actual) | Interventional | 2007-12-31 | Withdrawn (stopped due to Inadequate number of patients, lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for candesartan cilexetil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Hu | 2009 |
Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1997 |
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |